|  |  |  |
| --- | --- | --- |
| **Trial characteristic** | **Trials** | **Percentage** |
| **Total** | 2113 | 100 |
| Country |  |  |
| Denmark | 1019 | 48.2 |
| Finland | 231 | 10.9 |
| Iceland | 10 | 0.5 |
| Norway | 328 | 15.5 |
| Sweden | 525 | 24.8 |
| Intervention type |  |  |
| Medicinal product | 675 | 31.9 |
| Not medicinal product | 1438 | 68.1 |
| Main sponsor |  |  |
| Industry or mixed | 158 | 7.5 |
| Only non-industry | 1955 | 92.5 |
| Phase |  |  |
| I | 65 | 3.1 |
| I-II | 30 | 1.4 |
| II | 197 | 9.3 |
| II-III | 21 | 1 |
| III | 61 | 2.9 |
| IV | 240 | 11.4 |
| Not given | 1499 | 70.9 |
| Multicentric |  |  |
| Yes | 526 | 24.9 |
| No (monocentric) | 1587 | 75.1 |
| Enrollment (actual or anticipated) |  |  |
| 1 - 100 | 1464 | 69.3 |
| 100 - 500 | 515 | 24.4 |
| > 500 | 133 | 6.3 |
| Not given | 1 | 0 |
| Registration timing |  |  |
| prospective registration | 1257 | 59.5 |
| after trial start | 776 | 36.7 |
| after trial completion | 186 | 8.8 |
| after publication | 8 | 0.4 |
| start date not given | 80 | 3.8 |
| Completion year (actual or anticipated) |  |  |
| 2016 | 521 | 24.7 |
| 2017 | 528 | 25 |
| 2018 | 557 | 26.4 |
| 2019 | 507 | 24 |
| Status |  |  |
| Completed | 1675 | 79.3 |
| Terminated | 150 | 7.1 |
| Unknown status | 288 | 13.6 |